^
X
Professional Growth
Professional Tools
Astro Outreach

2019 ASTRO Annual Meeting

Home / Meetings and Education / Live Meetings / 2019 ASTRO Annual Meeting / Program / Meeting Highlights
Page Menu

Theranostics Workshop

Many new radiopharmaceutical therapies (RPTs) are now approved and many others are emerging for treatment of prostate cancer, neuroendocrine cancers and other cancers. Radiation oncologists are experts regarding the benefits and risks associated with various cancer therapeutic options and are perfectly positioned to help patients make the best choice for their particular situation, including the use of RPT’s. Radiation oncologists are certified to deliver these RPTs but many lack specific and updated training and therefore underutilize them. This one-half day training course is designed to teach clinical radiation oncologists everything they need to know to expand their practice into radiopharmaceutical therapy. It will provide a refresher on relevant physics, pharmacology, and radiobiology, as well as offer logistical and practical training in clinical use of radiopharmaceuticals. It will include specific breakout sessions on Ra-223, Lu-177 DOTATATE, Lu-177 PSMA agents, I-131 MIBG and Y-90 Microspheres. It will also cover important infrastructure, workflow and financial considerations. This special training course will enable radiation oncologists to provide the highest quality of patient-centered care in the use of RPTs.
 
Registration Category Registration Rate
Member $150
Nonmember  $150
Residents/Students Free

Saturday, September 14, 2019
1:00 p.m. - 6:00 p.m.

Program Outline:

Time Topic Speaker(s)
1:00 p.m. - 1:30 p.m. Introduction to Radiopharmaceutical Therapy Annick van den Abbeele, MD
1:30 p.m. - 2:15 p.m. Physics of RPTs
  • Imaging
  • Isotopes
  • Dosimetry methods
  • Radiation safety
 Robert Hobbs, PhD

Stephen Graves, PhD
2:15 p.m. - 2:45 p.m. Pharmacology and radiobiology of RPTs
  • Pharmacokinetics and Biodistribution
  • RBE
  • Radiation toxicities
 Susan Knox, MD, PhD

Ana Kiess, MD, PhD
2:45 p.m. - 3:30 p.m.  Clinical Studies of RPTs
  • Published controlled trials of Ra-223, Lu-177 DOTATATE, and I-131 MIBG
  • Ongoing trials of Lu-177 PSMA agents
  • Published reports of Y-90 microspheres
 Michael Morris, MD

Neeta Pandit-Taskar, MD
3:30 p.m. - 4:00 p.m. Infrastructure, Workflow, and Finances of RPTs John Buatti, MD
 
4:00 p.m. - 4:15 p.m. Break  
4:15 p.m. - 5:00 p.m. Breakout Sessions I:

These sessions will focus on practical aspects of specific RPTs including patient selection and indications, logistics of imaging and therapy, followup and potential toxicities.  These 2 successive sessions will have the same 5 options, and attendees will choose one per session.  There will be time reserved for Q&A.
  • Radium-223
  • Lu-177 DOTATATE
  • Lu-177 PSMA agents
  • I-131 MIBG
  • Y-90 Microspheres
 Richard Stock, MD (Ra-223)

Lilja Solnes, MD (Lu-177 DOTATATE)

Ana Kiess, MD, PhD (Lu-177 PSMA)

Neeta Pandit-Taskar, MD (I-131 MIBG)

Andrew Kennedy, MD  (Y-90 Microspheres)
 
5:00 p.m. - 5:15 p.m.  Break  
5:15 p.m. - 6:00 p.m.  Breakout Sessions II:

These sessions will focus on practical aspects of specific RPTs including patient selection and indications, logistics of imaging and therapy, followup and potential toxicities.  These 2 successive sessions will have the same 5 options, and attendees will choose one per session.  There will be time reserved for Q&A.
  • Radium-223
  • Lu-177 DOTATATE
  • Lu-177 PSMA agents
  • I-131 MIBG
  • Y-90 Microspheres
 Richard Stock, MD (Ra-223)

Lilja Solnes, MD (Lu-177 DOTATATE)

Ana Kiess, MD, PhD (Lu-177 PSMA)

Neeta Pandit-Taskar, MD (I-131 MIBG)

Andrew Kennedy, MD  (Y-90 Microspheres)
CLOSE